These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21766685)

  • 1. [Combination therapy of leptin and amylin for metabolic syndrome].
    Kusakabe T; Ebihara K; Nakao K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():705-10. PubMed ID: 21766685
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination therapy of amylin and leptin].
    Furuta H
    Nihon Rinsho; 2012 May; 70 Suppl 3():740-5. PubMed ID: 22768608
    [No Abstract]   [Full Text] [Related]  

  • 3. Insights into amylin-leptin synergy.
    Trevaskis JL; Parkes DG; Roth JD
    Trends Endocrinol Metab; 2010 Aug; 21(8):473-9. PubMed ID: 20413324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development.
    Chan JL; Roth JD; Weyer C
    J Investig Med; 2009 Oct; 57(7):777-83. PubMed ID: 20029268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?
    Trevaskis JL; Turek VF; Griffin PS; Wittmer C; Parkes DG; Roth JD
    Physiol Behav; 2010 May; 100(2):187-95. PubMed ID: 20206194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.
    Lloyd DJ; McCormick J; Helmering J; Kim KW; Wang M; Fordstrom P; Kaufman SA; Lindberg RA; Véniant MM
    Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E496-505. PubMed ID: 18160459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations.
    Roth JD; Trevaskis JL; Turek VF; Parkes DG
    Brain Res; 2010 Sep; 1350():86-94. PubMed ID: 20096672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy.
    Oike Y; Akao M; Kubota Y; Suda T
    Trends Mol Med; 2005 Oct; 11(10):473-9. PubMed ID: 16154386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome.
    Correia ML; Rahmouni K
    Diabetes Obes Metab; 2006 Nov; 8(6):603-10. PubMed ID: 17026484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
    Grundy SM
    Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM; Hachey DL; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction of transgenic mouse system expressing human islet amyloid polypeptide (IAPP)/amylin].
    Yagui K; Kanatsuka A; Makino H
    Nihon Rinsho; 1994 Oct; 52(10):2746-50. PubMed ID: 7983808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intracellular glucocorticoid reactivating enzyme, 11beta-HSD1 as a therapeutic target of obesity-diabetes syndrome].
    Masuzaki H
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():711-5. PubMed ID: 21766686
    [No Abstract]   [Full Text] [Related]  

  • 15. Human leptin deficiency and resistance.
    Mathew I; Sharma SK
    J Assoc Physicians India; 2000 Oct; 48(10):1032. PubMed ID: 11200911
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin.
    Osto M; Wielinga PY; Alder B; Walser N; Lutz TA
    Physiol Behav; 2007 Aug; 91(5):566-72. PubMed ID: 17481674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mazindol].
    Mori Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():683-6. PubMed ID: 21766681
    [No Abstract]   [Full Text] [Related]  

  • 18. [Energy homeostasis regulated by an adipocyte-derived hormone--mechanism of leptin resistance and role of hypothalamic melanocortin signaling].
    Masuzaki H; Tanaka T; Ebihara K; Hosoda K; Nakao K
    Nihon Rinsho; 2009 Feb; 67(2):287-96. PubMed ID: 19202901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sibutramine and its adequate usage].
    Nagayama D; Shirai K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():678-82. PubMed ID: 21766680
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
    Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
    Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.